A PI3K p110α-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice

• Published in: Oncoimmunology Vol. 7; no. 5; p. e1421890
• Main Authors: Choi, Jae-Hyeog, Kim, Ki Hyang, Roh, Kug-Hwan, Jung, Hana, Lee, Anbok, Lee, Ji-Young, Song, Joo Yeon, Park, Seung Jae, Kim, Ilhwan, Lee, Won-Sik, Seo, Su-Kil, Choi, Il-Whan, Fu, Yang-Xin, Yea, Sung Su, Park, SaeGwang
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 04.05.2018; Taylor & Francis Group
• Subjects: anti-HER2/neu antibody; anti-tumor immunity; breast cancer; Original Research; PI3K, p110α-selective inhibitor; anti-HER2/neu antibody; breast cancer; PI3K, p110α-selective inhibitor; anti-tumor immunity

Combination therapies with phosphoinositide 3-kinase (PI3K) inhibitors and trastuzumab (anti-human epidermal growth factor receptor [HER]2/neu antibody) are effective against HER2+ breast cancer. Isoform-selective PI3K inhibitors elicit anti-tumor immune responses that are distinct from those induce...